Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

Stephen T. Keir, John M. Maris, Richard Lock, E. Anders Kolb, Richard Gorlick, Hernan Carol, Christopher L. Morton, C. Patrick Reynolds, Min H. Kang, Amy Watkins, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Background: Sorafenib is an inhibitor of multiple kinases (e.g., VEGF receptors, PDGFR, FLT3, RET, BRAF, KIT) and is approved by FDA for treatment of two adult cancers. The activity of sorafenib was evaluated against the PPTP's in vitro and in vivo panels. Procedures: Sorafenib was evaluated against the PPTP in vitro panel using 96-hr exposure at concentrations ranging from 1.0 nM to 10.0 μM. It was tested against the PPTP in vivo panels at a dose of 60 mg/kg administered by oral gavage daily for 5 days per week, repeated for 6 weeks. Results: In vitro sorafenib demonstrated cytotoxic activity, with a median IC50 value of 4.3 μM. Twenty of 23 cell lines had IC50 values between 1.0 and 10.0 μM. A single cell line (Kasumi-1) with an activating KIT mutation had an IC50 value <1.0 μM (IC50 = 0.02 μM). In vivo sorafenib induced significant differences in event-free survival (EFS) distribution compared to control in 27 of 36 (75%) of the evaluable solid tumor xenografts and in 1 of 8 (12.5%) of the evaluable ALL xenografts. Sorafenib induced tumor growth inhibition meeting criteria for intermediate activity (EFS T/C) in 15 of 34 (44%) evaluable solid tumor xenografts. No xenografts achieved an objective response. Conclusions: The primary in vitro activity of sorafenib was noted at concentrations above 1 μM, with the exception of a more sensitive cell line with an activating KIT mutation. The primary in vivo effect for sorafenib was tumor growth inhibition, which was observed across multiple histotypes.

Original languageEnglish (US)
Pages (from-to)1126-1133
Number of pages8
JournalPediatric Blood and Cancer
Volume55
Issue number6
DOIs
StatePublished - Dec 2010

Fingerprint

Phosphotransferases
Pediatrics
Heterografts
Inhibitory Concentration 50
Neoplasms
Cell Line
Disease-Free Survival
Mutation
Vascular Endothelial Growth Factor Receptor
sorafenib
Growth
In Vitro Techniques
N-propyl-4-phenyl-1,2,3,6-tetrahydropyridine

Keywords

  • Developmental therapeutics
  • Preclinical testing
  • Tyrosine kinases

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Keir, S. T., Maris, J. M., Lock, R., Kolb, E. A., Gorlick, R., Carol, H., ... Smith, M. A. (2010). Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatric Blood and Cancer, 55(6), 1126-1133. https://doi.org/10.1002/pbc.22712

Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. / Keir, Stephen T.; Maris, John M.; Lock, Richard; Kolb, E. Anders; Gorlick, Richard; Carol, Hernan; Morton, Christopher L.; Reynolds, C. Patrick; Kang, Min H.; Watkins, Amy; Houghton, Peter J.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 55, No. 6, 12.2010, p. 1126-1133.

Research output: Contribution to journalArticle

Keir, ST, Maris, JM, Lock, R, Kolb, EA, Gorlick, R, Carol, H, Morton, CL, Reynolds, CP, Kang, MH, Watkins, A, Houghton, PJ & Smith, MA 2010, 'Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 55, no. 6, pp. 1126-1133. https://doi.org/10.1002/pbc.22712
Keir, Stephen T. ; Maris, John M. ; Lock, Richard ; Kolb, E. Anders ; Gorlick, Richard ; Carol, Hernan ; Morton, Christopher L. ; Reynolds, C. Patrick ; Kang, Min H. ; Watkins, Amy ; Houghton, Peter J. ; Smith, Malcolm A. / Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2010 ; Vol. 55, No. 6. pp. 1126-1133.
@article{2de0f19d3df2425685ccf4c9a4f25c1b,
title = "Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program",
abstract = "Background: Sorafenib is an inhibitor of multiple kinases (e.g., VEGF receptors, PDGFR, FLT3, RET, BRAF, KIT) and is approved by FDA for treatment of two adult cancers. The activity of sorafenib was evaluated against the PPTP's in vitro and in vivo panels. Procedures: Sorafenib was evaluated against the PPTP in vitro panel using 96-hr exposure at concentrations ranging from 1.0 nM to 10.0 μM. It was tested against the PPTP in vivo panels at a dose of 60 mg/kg administered by oral gavage daily for 5 days per week, repeated for 6 weeks. Results: In vitro sorafenib demonstrated cytotoxic activity, with a median IC50 value of 4.3 μM. Twenty of 23 cell lines had IC50 values between 1.0 and 10.0 μM. A single cell line (Kasumi-1) with an activating KIT mutation had an IC50 value <1.0 μM (IC50 = 0.02 μM). In vivo sorafenib induced significant differences in event-free survival (EFS) distribution compared to control in 27 of 36 (75{\%}) of the evaluable solid tumor xenografts and in 1 of 8 (12.5{\%}) of the evaluable ALL xenografts. Sorafenib induced tumor growth inhibition meeting criteria for intermediate activity (EFS T/C) in 15 of 34 (44{\%}) evaluable solid tumor xenografts. No xenografts achieved an objective response. Conclusions: The primary in vitro activity of sorafenib was noted at concentrations above 1 μM, with the exception of a more sensitive cell line with an activating KIT mutation. The primary in vivo effect for sorafenib was tumor growth inhibition, which was observed across multiple histotypes.",
keywords = "Developmental therapeutics, Preclinical testing, Tyrosine kinases",
author = "Keir, {Stephen T.} and Maris, {John M.} and Richard Lock and Kolb, {E. Anders} and Richard Gorlick and Hernan Carol and Morton, {Christopher L.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Amy Watkins and Houghton, {Peter J.} and Smith, {Malcolm A.}",
year = "2010",
month = "12",
doi = "10.1002/pbc.22712",
language = "English (US)",
volume = "55",
pages = "1126--1133",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program

AU - Keir, Stephen T.

AU - Maris, John M.

AU - Lock, Richard

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Carol, Hernan

AU - Morton, Christopher L.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Watkins, Amy

AU - Houghton, Peter J.

AU - Smith, Malcolm A.

PY - 2010/12

Y1 - 2010/12

N2 - Background: Sorafenib is an inhibitor of multiple kinases (e.g., VEGF receptors, PDGFR, FLT3, RET, BRAF, KIT) and is approved by FDA for treatment of two adult cancers. The activity of sorafenib was evaluated against the PPTP's in vitro and in vivo panels. Procedures: Sorafenib was evaluated against the PPTP in vitro panel using 96-hr exposure at concentrations ranging from 1.0 nM to 10.0 μM. It was tested against the PPTP in vivo panels at a dose of 60 mg/kg administered by oral gavage daily for 5 days per week, repeated for 6 weeks. Results: In vitro sorafenib demonstrated cytotoxic activity, with a median IC50 value of 4.3 μM. Twenty of 23 cell lines had IC50 values between 1.0 and 10.0 μM. A single cell line (Kasumi-1) with an activating KIT mutation had an IC50 value <1.0 μM (IC50 = 0.02 μM). In vivo sorafenib induced significant differences in event-free survival (EFS) distribution compared to control in 27 of 36 (75%) of the evaluable solid tumor xenografts and in 1 of 8 (12.5%) of the evaluable ALL xenografts. Sorafenib induced tumor growth inhibition meeting criteria for intermediate activity (EFS T/C) in 15 of 34 (44%) evaluable solid tumor xenografts. No xenografts achieved an objective response. Conclusions: The primary in vitro activity of sorafenib was noted at concentrations above 1 μM, with the exception of a more sensitive cell line with an activating KIT mutation. The primary in vivo effect for sorafenib was tumor growth inhibition, which was observed across multiple histotypes.

AB - Background: Sorafenib is an inhibitor of multiple kinases (e.g., VEGF receptors, PDGFR, FLT3, RET, BRAF, KIT) and is approved by FDA for treatment of two adult cancers. The activity of sorafenib was evaluated against the PPTP's in vitro and in vivo panels. Procedures: Sorafenib was evaluated against the PPTP in vitro panel using 96-hr exposure at concentrations ranging from 1.0 nM to 10.0 μM. It was tested against the PPTP in vivo panels at a dose of 60 mg/kg administered by oral gavage daily for 5 days per week, repeated for 6 weeks. Results: In vitro sorafenib demonstrated cytotoxic activity, with a median IC50 value of 4.3 μM. Twenty of 23 cell lines had IC50 values between 1.0 and 10.0 μM. A single cell line (Kasumi-1) with an activating KIT mutation had an IC50 value <1.0 μM (IC50 = 0.02 μM). In vivo sorafenib induced significant differences in event-free survival (EFS) distribution compared to control in 27 of 36 (75%) of the evaluable solid tumor xenografts and in 1 of 8 (12.5%) of the evaluable ALL xenografts. Sorafenib induced tumor growth inhibition meeting criteria for intermediate activity (EFS T/C) in 15 of 34 (44%) evaluable solid tumor xenografts. No xenografts achieved an objective response. Conclusions: The primary in vitro activity of sorafenib was noted at concentrations above 1 μM, with the exception of a more sensitive cell line with an activating KIT mutation. The primary in vivo effect for sorafenib was tumor growth inhibition, which was observed across multiple histotypes.

KW - Developmental therapeutics

KW - Preclinical testing

KW - Tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=77958598570&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77958598570&partnerID=8YFLogxK

U2 - 10.1002/pbc.22712

DO - 10.1002/pbc.22712

M3 - Article

C2 - 20672370

AN - SCOPUS:77958598570

VL - 55

SP - 1126

EP - 1133

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 6

ER -